Glioblastoma
Conditions
Keywords
FDG, PET/CT very early response (48 hrs)
Brief summary
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Detailed description
PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival. OUTLINE: Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
Interventions
PROCEDUREComputed Tomography
Undergo FDG PET/CT
RADIATIONFludeoxyglucose F-18
Undergo FDG PET/CT
PROCEDUREPositron Emission Tomography
Undergo FDG PET/CT
Sponsors
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients with histologically proven high grade glioma * Intention to start therapy
Exclusion criteria
* Severe psychiatric illness * Inability to give written consent * Breast feeding / pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in glucose uptake | From baseline up to 48 hours | Standardized uptake values (SUV) will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established. |
| Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria | One PET/CT 48 hours after start of therapy | SUV will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJohannes Czernin, MD
UCLA / Jonsson Comprehensive Cancer Center
Outcome results
None listed